What is Astria Therapeutics Inc's earnings per share (EPS)?

Astria Therapeutics Inc (ATXS) reported diluted earnings per share of -$1.68 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Astria Therapeutics Inc Financials

ATXS

FY2024 annual

Revenue Not reported for FY2024

Net Income -$94.3M -29.3% YoY

EPS (Diluted) -$1.68 YoY not available

Free Cash Flow -$81.5M -19.1% YoY

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2025 Currency USD FYE December

This page shows Astria Therapeutics Inc (ATXS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATXS FY2024 2026-08-15

Astria is funding a research-heavy operating model with new equity while keeping a very light liability base.

FY2024 cash of $59.8M was lower than that year's operating cash use of $81.2M, so the company could not sustain its spending pace from existing cash alone; the matching response was a $157.2M financing inflow and share count rising to 56.4M from 41.0M in FY2023. That link between cash burn, equity financing, and dilution is the core operating mechanic here.

Losses are cash-real rather than accounting-heavy: net income of -$94.3M, operating cash flow of -$81.2M, and free cash flow of -$81.5M sit close together, so reported losses are largely showing up in cash. With capex at only $325K, most cash use is tied to research activity and corporate overhead, not to building a capital-intensive asset base.

The balance sheet is conservative on debt: liabilities were only $23.1M against assets of $342.4M, and no long-term debt was reported. That keeps solvency pressure low, but it also means the business is financed mainly by shareholders rather than lenders, which explains the sharp rise in share count over the last two fiscal years.

Financial Health Signals

Financial health score not available

Astria Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Astria Therapeutics Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Astria Therapeutics Inc reported a net loss of $94.3M while operations used $81.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$94.3M

YoY-29.3%

Astria Therapeutics Inc reported -$94.3M in net income in fiscal year 2024. This represents a decrease of 29.3% from the prior year.

EPS (Diluted)

-$1.68

Astria Therapeutics Inc earned -$1.68 per diluted share (EPS) in fiscal year 2024.

Revenue

Not reported for fiscal year 2024.

EBITDA

Not reported for fiscal year 2024.

Cash & Balance Sheet

Free Cash Flow

-$81.5M

YoY-19.1%

Astria Therapeutics Inc recorded an outflow of $81.5M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents a decrease of 19.1% from the prior year.

Cash & Debt

$59.8M

YoY-65.9%

5Y CAGR+43.3%

10Y CAGR+15.1%

Astria Therapeutics Inc held $59.8M in cash as of fiscal year 2024; long-term debt is not reported for that period.

Shares Outstanding

56M

Astria Therapeutics Inc had 56M shares outstanding in fiscal year 2024.

Dividends Per Share

Not reported for fiscal year 2024.

Margins & Returns

Return on Equity

-29.5%

YoY+0.5pp

5Y CAGR+44.1pp

Astria Therapeutics Inc's ROE was -29.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 0.5 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2024.

Operating Margin

Not reported for fiscal year 2024.

Net Margin

Not reported for fiscal year 2024.

Capital Allocation

R&D Spending

$77.1M

YoY+83.0%

5Y CAGR+33.3%

10Y CAGR+17.3%

Astria Therapeutics Inc invested $77.1M in research and development in fiscal year 2024. This represents an increase of 83.0% from the prior year.

Capital Expenditures

$325K

YoY+1200.0%

5Y CAGR+93.4%

Astria Therapeutics Inc invested $325K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 1200.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2024.

ATXS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATXS annual income statement

Metric	TTM	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Revenue	N/A	N/A	N/A	N/A	N/A	$0	N/A	$0-100.0%	$500K	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$77.1M+83.0%	$42.1M+22.9%	$34.3M+120.3%	$15.6M-39.2%	$25.6M+39.7%	$18.3M+7.5%	$17.0M-8.8%	$18.7M-26.6%	$25.4M+10.5%	$23.0M+46.8%	$15.7M+12.1%	$14.0M
SG&A Expenses	N/A	$34.5M+34.0%	$25.7M+33.6%	$19.2M+29.9%	$14.8M+25.0%	$11.8M+35.0%	$8.8M-6.0%	$9.3M+4.7%	$8.9M-11.8%	$10.1M+17.1%	$8.6M+43.9%	$6.0M+45.3%	$4.1M
Operating Income	N/A	-$111.6M-34.4%	-$83.0M-55.2%	-$53.5M+72.6%	-$195.0M-420.8%	-$37.4M-38.2%	-$27.1M-2.7%	-$26.4M+2.7%	-$27.1M+23.8%	-$35.6M-12.3%	-$31.7M-46.0%	-$21.7M-19.7%	-$18.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$100K-78.4%	$462K-44.8%	$837K-14.4%	$978K+374.8%	$206K	N/A
Net Income	N/A	-$94.3M-29.3%	-$72.9M-40.6%	-$51.8M+73.4%	-$194.9M-422.6%	-$37.3M-41.9%	-$26.3M-1.6%	-$25.9M+5.5%	-$27.4M+24.1%	-$36.1M-10.5%	-$32.6M-49.1%	-$21.9M-20.8%	-$18.1M
EPS (Diluted)	—	-$1.68	-$2.42	-$3.55	-$24.58	-$12.20	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$706K	N/A	N/A	N/A	$0	N/A	N/A	N/A
R&D Expenses	$24.1M-6.9%	$25.9M-6.6%	$27.8M	N/A	$20.5M-1.0%	$20.7M+31.7%	$15.7M	N/A
SG&A Expenses	$10.7M+8.0%	$9.9M+7.2%	$9.2M	N/A	$8.5M+5.1%	$8.1M-3.9%	$8.4M	N/A
Operating Income	-$34.1M+4.8%	-$35.8M+3.2%	-$37.0M	N/A	-$29.0M-0.7%	-$28.8M-19.3%	-$24.1M	N/A
Net Income	-$31.6M+4.3%	-$33.1M+1.9%	-$33.7M	N/A	-$24.5M-1.5%	-$24.2M-21.3%	-$19.9M	N/A
EPS (Diluted)	-$0.55+3.5%	-$0.57+1.7%	-$0.58	N/A	-$0.42+2.3%	-$0.43-13.2%	-$0.38	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

ATXS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATXS annual balance sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Total Assets	$342.4M+34.4%	$254.7M+10.4%	$230.6M+80.9%	$127.5M+168.7%	$47.5M+13.6%	$41.8M+6.7%	$39.2M+118.9%	$17.9M-55.5%	$40.2M-37.3%	$64.2M+302.0%	$16.0M	N/A
Current Assets	$334.6M+33.4%	$250.9M+10.2%	$227.7M+79.2%	$127.1M+174.3%	$46.3M+18.9%	$39.0M+0.1%	$38.9M+122.8%	$17.5M-55.8%	$39.5M-37.8%	$63.6M+323.1%	$15.0M	N/A
Cash & Equivalents	$59.8M-65.9%	$175.5M+755.2%	$20.5M-76.3%	$86.5M+247.0%	$24.9M+151.8%	$9.9M-35.3%	$15.3M-6.6%	$16.4M-30.6%	$23.6M-62.4%	$62.8M+328.0%	$14.7M-51.9%	$30.5M
Accounts Receivable	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$23.1M+100.0%	$11.6M+22.7%	$9.4M+81.0%	$5.2M-23.3%	$6.8M+12.0%	$6.1M+43.4%	$4.2M-30.8%	$6.1M-45.1%	$11.1M-18.7%	$13.7M-84.6%	$89.0M	N/A
Current Liabilities	$19.1M+65.6%	$11.6M+27.5%	$9.1M+74.1%	$5.2M-18.6%	$6.4M+27.0%	$5.0M+20.6%	$4.2M-30.7%	$6.0M-27.7%	$8.3M+7.0%	$7.8M+83.7%	$4.2M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2.5M-57.1%	$5.8M	N/A	$5.0M	N/A
Total Equity	$319.3M+31.3%	$243.1M+9.9%	$221.2M+80.9%	$122.3M+200.7%	$40.7M+13.9%	$35.7M+2.2%	$34.9M+196.3%	$11.8M-59.5%	$29.1M-42.4%	$50.5M+169.1%	-$73.1M-40.0%	-$52.2M
Retained Earnings	-$674.8M-16.2%	-$580.5M-14.4%	-$507.6M-11.4%	-$455.8M-74.7%	-$260.9M-16.7%	-$223.6M-13.3%	-$197.3M-15.1%	-$171.4M-19.0%	-$144.1M-33.4%	-$108.0M-43.3%	-$75.4M	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$271.9M-3.6%	$281.9M-9.2%	$310.4M-9.3%	$342.4M-5.3%	$361.6M-1.7%	$368.0M-2.9%	$378.8M+48.7%	$254.7M
Current Assets	$253.5M-5.6%	$268.6M-11.3%	$303.0M-9.5%	$334.6M-4.9%	$351.9M-1.7%	$357.9M-4.4%	$374.5M+49.2%	$250.9M
Cash & Equivalents	$96.3M+26.2%	$76.3M+40.3%	$54.4M-9.1%	$59.8M-26.1%	$80.9M-7.2%	$87.2M-49.3%	$172.0M-2.0%	$175.5M
Accounts Receivable	$17.2M	N/A	N/A	$0	N/A	N/A	N/A	N/A
Total Liabilities	$38.6M+80.3%	$21.4M+1.5%	$21.1M-8.7%	$23.1M+15.6%	$20.0M-4.4%	$20.9M+88.9%	$11.1M-4.1%	$11.6M
Current Liabilities	$23.5M+30.3%	$18.0M+3.5%	$17.4M-8.9%	$19.1M+21.7%	$15.7M-3.9%	$16.4M+47.8%	$11.1M-4.1%	$11.6M
Total Equity	$233.3M-10.5%	$260.5M-9.9%	$289.3M-9.4%	$319.3M-6.6%	$341.7M-1.6%	$347.1M-5.6%	$367.7M+51.3%	$243.1M
Retained Earnings	-$773.2M-4.3%	-$741.6M-4.7%	-$708.5M-5.0%	-$674.8M-3.9%	-$649.2M-3.9%	-$624.6M-4.0%	-$600.5M-3.4%	-$580.5M

Not reported in any period shown, so not listed: Inventory, Goodwill.

ATXS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATXS annual cash flow statement

Metric	TTM	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Cash Flow	-$119.7M	-$81.2M-18.7%	-$68.4M-57.2%	-$43.5M-44.4%	-$30.2M+7.2%	-$32.5M-22.3%	-$26.6M-13.2%	-$23.5M+12.6%	-$26.8M+18.3%	-$32.9M-10.3%	-$29.8M-46.0%	-$20.4M-24.7%	-$16.4M
Capital Expenditures	N/A	$325K+1200.0%	$25K-72.5%	$91K+333.3%	$21K-36.4%	$33K+175.0%	$12K	N/A	$57K-87.6%	$459K+9.0%	$421K+84.6%	$228K+430.2%	$43K
Free Cash Flow	N/A	-$81.5M-19.1%	-$68.5M-57.0%	-$43.6M-44.6%	-$30.2M+7.2%	-$32.5M-22.3%	-$26.6M	N/A	-$26.9M+19.3%	-$33.3M-10.3%	-$30.2M-46.4%	-$20.6M-25.8%	-$16.4M
Investing Cash Flow	$135.1M	-$191.9M-242.1%	$135.1M+180.8%	-$167.1M-1231.2%	-$12.6M-299.3%	$6.3M+254.3%	-$4.1M+81.4%	-$21.9M-247.2%	$14.9M+196.1%	-$15.5M-3579.3%	-$421K	N/A	N/A
Financing Cash Flow	N/A	$157.2M+77.8%	$88.4M-38.9%	$144.7M+38.8%	$104.3M+155.2%	$40.9M+59.5%	$25.6M-42.2%	$44.3M+837.3%	$4.7M-48.4%	$9.2M-88.3%	$78.3M	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$32.3M+10.4%	-$36.1M-6.0%	-$34.0M-95.9%	-$17.4M+37.9%	-$28.0M-66.5%	-$16.8M+12.1%	-$19.1M+36.9%	-$30.2M
Capital Expenditures	$0	N/A	N/A	$0-100.0%	$20K	N/A	N/A	$16K
Free Cash Flow	-$32.3M	N/A	N/A	-$17.4M+38.0%	-$28.0M	N/A	N/A	-$30.3M
Investing Cash Flow	$52.3M-9.9%	$58.0M+102.9%	$28.6M+869.0%	-$3.7M-160.1%	$6.2M+109.1%	-$68.1M+46.0%	-$126.2M-6161.5%	-$2.0M
Financing Cash Flow	N/A	N/A	N/A	$0-100.0%	$15.3M+16177.7%	$94K-99.9%	$141.8M+61.2%	$88.0M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ATXS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

ATXS annual financial ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-5418.8%	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-5472.8%	N/A	N/A	N/A	N/A
Return on Equity	-29.5%+0.5pp	-30.0%-6.6pp	-23.4%+135.9pp	-159.4%-67.6pp	-91.7%-18.1pp	-73.6%+0.4pp	-74.0%+158.0pp	-232.1%-108.1pp	-124.0%-59.4pp	-64.6%	N/A	N/A
Return on Assets	-27.5%+1.1pp	-28.6%-6.2pp	-22.5%+130.4pp	-152.9%-74.3pp	-78.6%-15.7pp	-62.9%+3.1pp	-66.0%+86.8pp	-152.9%-63.2pp	-89.7%-38.8pp	-50.8%+86.2pp	-137.1%	N/A
Current Ratio	17.49-4.2x	21.73-3.4x	25.13+0.7x	24.42+17.2x	7.25-0.5x	7.74-1.6x	9.33+6.4x	2.90-1.8x	4.75-3.4x	8.17+4.6x	3.55	N/A
Debt-to-Equity	0.070.0x	0.050.0x	0.040.0x	0.04-0.1x	0.170.0x	0.170.0x	0.12-0.1x	0.210.0x	0.20-0.1x	0.27	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-5378.6%	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Margin	-4830.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-4482.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-13.6%-0.9pp	-12.7%-1.0pp	-11.7%	N/A	-7.2%-0.2pp	-7.0%-1.5pp	-5.4%	N/A
Return on Assets	-11.6%+0.1pp	-11.7%-0.9pp	-10.9%	N/A	-6.8%-0.2pp	-6.6%-1.3pp	-5.3%	N/A
Current Ratio	10.78-4.1x	14.89-2.5x	17.39-0.1x	17.49-4.9x	22.38+0.5x	21.87-12.0x	33.83+12.1x	21.73
Debt-to-Equity	0.17+0.1x	0.080.0x	0.070.0x	0.070.0x	0.060.0x	0.060.0x	0.030.0x	0.05
FCF Margin	-4574.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Prothena PRTA

$485.1M

Inhibrx Biosciences Inc INBX

$1.5B

Lexicon Pharmaceuticals Inc LXRX

$1.0B

Diamedica Therapeutics Inc DMAC

$351.6M

Replimune Group REPL

$1.4B

Where Astria Therapeutics Inc Ranks

Frequently Asked Questions

Is Astria Therapeutics Inc profitable?

No, Astria Therapeutics Inc (ATXS) reported a net income of -$94.3M in fiscal year 2024.

What is Astria Therapeutics Inc's return on equity (ROE)?

Astria Therapeutics Inc (ATXS) has a return on equity of -29.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Astria Therapeutics Inc's free cash flow?

Astria Therapeutics Inc (ATXS) recorded an outflow of $81.5M in free cash flow during fiscal year 2024. This represents a -19.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Astria Therapeutics Inc's operating cash flow?

Astria Therapeutics Inc (ATXS) recorded an outflow of $81.2M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

What are Astria Therapeutics Inc's total assets?

Astria Therapeutics Inc (ATXS) had $342.4M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Astria Therapeutics Inc's capital expenditures?

Astria Therapeutics Inc (ATXS) invested $325K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Astria Therapeutics Inc spend on research and development?

Astria Therapeutics Inc (ATXS) invested $77.1M in research and development during fiscal year 2024.

How many shares does Astria Therapeutics Inc have outstanding?

Astria Therapeutics Inc (ATXS) had 56M shares outstanding as of fiscal year 2024.

What is Astria Therapeutics Inc's current ratio?

Astria Therapeutics Inc (ATXS) had a current ratio of 17.49 as of fiscal year 2024, which is generally considered healthy.

What is Astria Therapeutics Inc's debt-to-equity ratio?

Astria Therapeutics Inc (ATXS) had a debt-to-equity ratio of 0.07 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Astria Therapeutics Inc's return on assets (ROA)?

Astria Therapeutics Inc (ATXS) had a return on assets of -27.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Astria Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Astria Therapeutics Inc (ATXS) had $59.8M in cash against an annual operating cash burn of $81.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Astria Therapeutics Inc's Piotroski F-Score?

Astria Therapeutics Inc (ATXS) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Astria Therapeutics Inc's earnings high quality?

Astria Therapeutics Inc (ATXS) reported a net loss of $94.3M while operations used $81.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.